Healthcare / Medical DevicesShenzhen
$12.34
-0.25 (-1.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $90.9M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
30.1x
↑EV/EBITDA
18.1x
↑ROE
8.0%
↑Gross Margin
35.6%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.5%
FCF CAGR
+29.6%
FCF margin
14.0%
FCF / Net income
1.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $986.2M · net income $82.0M · FCF $138.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $986.2M | $986.2M | $984.0M | $884.3M | $1.07B |
| Net Income | $82.0M | $82.0M | $61.4M | $34.4M | $-32.4M |
| EBITDA | $112.6M | $112.6M | $92.1M | $66.3M | $-11.6M |
| EPS | 0.38 | 0.38 | 0.28 | 0.16 | -0.15 |
| Gross Margin | 35.6% | 35.6% | 35.1% | 30.9% | 23.7% |
| Operating Margin | 10.7% | 10.7% | 6.2% | 2.5% | -1.5% |
| Net Margin | 8.3% | 8.3% | 6.2% | 3.9% | -3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.19 | 0.13 | 0.14 |
| Current Ratio | 2.83 | 2.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $138.4M | $138.4M | $90.9M | $61.2M | $63.6M |
| Returns | |||||
| ROE | 8.0% | 8.0% | 6.2% | 3.3% | -3.2% |
| Valuation | |||||
| P/E | 30.10 | 30.10 | 45.99 | 71.95 | — |
| EV/EBITDA | 18.08 | 18.08 | 24.41 | 29.28 | — |
| P/B | 2.62 | 2.62 | 2.83 | 2.38 | 2.23 |
| Growth & Yield | |||||
| Revenue Growth | 0.2% | 0.2% | 11.3% | -17.0% | — |
| EPS Growth | 33.1% | 33.1% | 77.0% | 206.5% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
42.8%
EPS terminal req.
$1.09
Spread vs growth
-9.6%
5Y implied EPS CAGR
28.6%
EPS terminal req.
$1.32
Spread vs growth
4.5%
10Y implied EPS CAGR
18.9%
EPS terminal req.
$2.13
Spread vs growth
14.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.4%
Start / end P/E
51.6x → 32.8x
EPS bridge
0.28 → 0.38
Residual
-12.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.